Biotechnology Valuation: An Introductory Guide

by Karl Keegan

Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start."
― Chris Blackwell , Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians."
― Steve Winokur , Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value."
― Dr L.M. Allan , Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic."
― Deirdre Y. Gillespie , MD, President & CEO, La Jolla Pharmaceutical Company

224 pages, Hardcover

First published November 21, 2008

Reviews

[Skywalker Hu · Rating 3 out of 5]

As an investment banker whose group does some biotech deals, I wanted to use this book as a self-study guide for biotech financial modeling. However, the walk-through is not there, and I doubt some numbers and/or formula given are just wrong.

[Jose Parra]

Interesting project valuation example in page 122 using backward dinámica programming